Introduction:
Aptar Pharma plans to expand its manufacturing capacity and capabilities in New York, USA.
Features:
This expansion involves a building extension, which will contribute an extra 28,500 sq. ft. to the manufacturing footprint, bolstering warehousing, cleanroom, and manufacturing capabilities on-site.
This expansion of the facility offers a larger, state-of-the-art manufacturing space, serving not only to enhance established operations but also to facilitate greater localisation in order to better support the requirements.
The facility's manufacturing capabilities will undergo further expansion to provide even more innovative product solutions and increase production capacity.
This expansion represents a crucial move in the next stage of global growth strategy aimed at ultimately leading to benefits for patients.
This investment will enable to meet the rising demand for its proprietary drug delivery systems in North America.
To address the increasing demand for systemic nasal delivery by patients, there is a significant expansion underway in the manufacturing capacity for the exclusive Unidose (UDS) Nasal Spray Systems.
The construction of this new environmentally controlled good manufacturing practise (GMP) production area is slated for full operational readiness by early 2025.
Specifications:
Name Aptar Pharma
Type Expansion
Year 2025
